Serum Levels of Soluble CD163 and CXCL5 May Be Predictive Markers for Immune-related Adverse Events in Patients with Advanced Melanoma Treated with Nivolumab: a Pilot Study

Overview

Journal Oncotarget

Specialty Oncology

Date 2018 Apr 13

PMID 29643991

Citations 45

Authors

Taku Fujimura

Yota Sato

Kayo Tanita

Yumi Kambayashi

Atsushi Otsuka

Yasuhiro Fujisawa

Koji Yoshino

Shigeto Matsushita

Takeru Funakoshi

Hiroo Hata

Yuki Yamamoto

Hiroshi Uchi

Yumi Nonomura

Ryota Tanaka

Megumi Aoki

Keisuke Imafuku

Hisako Okuhira

Sadanori Furudate

Takanori Hidaka

Setsuya Aiba

Affiliations

Soon will be listed here.

Abstract

Antibodies against PD-1, such as nivolumab and pembrolizumab, are widely used in the treatment of various cancers including advanced melanoma. The anti-PD-1 Ab significantly prolongs survival in patients with metastatic melanoma, and its administration in combination with local or systemic therapy may also lead to improved outcomes. Although anti-PD-1 Ab-based combined therapy might be effective for the treatment of advanced melanoma, the associated risk of irAEs is an important consideration. Therefore, being able to predict irAEs is of great interest to oncologists. The purpose of this study was to evaluate the value of using serum levels of sCD163 and CXCL5 to predict irAEs in patients with advanced melanoma who were administered nivolumab. To this end, we analyzed these serum levels in 46 cases of advanced melanoma treated with nivolumab. In addition, the tumor stroma was evaluated by immunohistochemistry and immunofluorescence. We measured the serum levels of sCD163 and CXCL5 on day 0 (immediately before nivolumab administration) and day 42. The serum absolute levels of sCD163 were significantly increased in patients who developed AEs ( = 0.0018). Although there was no significant difference in serum levels of CXCL5, the absolute value of CXCL5 could at least be a supportive marker for the increased absolute levels of serum sCD163. This study suggests that sCD163 and CXCL5 may serve as possible prognostic biomarkers for irAEs in patients with advanced melanoma treated with nivolumab.

Citing Articles

Revolutionary Cancer Therapy for Personalization and Improved Efficacy: Strategies to Overcome Resistance to Immune Checkpoint Inhibitor Therapy.

Almawash S Cancers (Basel). 2025; 17(5).

PMID: 40075727 PMC: 11899125. DOI: 10.3390/cancers17050880.

Ezdoglian A, Tsang-A-Sjoe M, Khodadust F, Burchell G, Jansen G, de Gruijl T Cancer Metastasis Rev. 2025; 44(1):35.

PMID: 39982537 PMC: 11845441. DOI: 10.1007/s10555-025-10246-6.

Non-Invasive Predictive Biomarkers for Immune-Related Adverse Events Due to Immune Checkpoint Inhibitors.

Ponvilawan B, Khan A, Subramanian J, Bansal D Cancers (Basel). 2024; 16(6).

PMID: 38539558 PMC: 10968874. DOI: 10.3390/cancers16061225.

Pulmonary toxicity of immune checkpoint immunotherapy.

Ghanbar M, Suresh K J Clin Invest. 2024; 134(2).

PMID: 38226621 PMC: 10786690. DOI: 10.1172/JCI170503.

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.

Liang Y, Maeda O, Ando Y Jpn J Clin Oncol. 2024; 54(4):365-375.

PMID: 38183211 PMC: 11771318. DOI: 10.1093/jjco/hyad184.

References

Yue E, Sparks R, Polam P, Modi D, Douty B, Wayland B . INCB24360 (Epacadostat), a Highly Potent and Selective Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitor for Immuno-oncology. ACS Med Chem Lett. 2017; 8(5):486-491. PMC: 5430407. DOI: 10.1021/acsmedchemlett.6b00391. View

Wolchok J, Kluger H, Callahan M, Postow M, Rizvi N, Lesokhin A . Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369(2):122-33. PMC: 5698004. DOI: 10.1056/NEJMoa1302369. View

Rumble J, Huber A, Krishnamoorthy G, Srinivasan A, Giles D, Zhang X . Neutrophil-related factors as biomarkers in EAE and MS. J Exp Med. 2015; 212(1):23-35. PMC: 4291533. DOI: 10.1084/jem.20141015. View

Buckland J . Rheumatoid arthritis: citrullination alters the inflammatory properties of chemokines in inflammatory arthritis. Nat Rev Rheumatol. 2014; 10(8):446. DOI: 10.1038/nrrheum.2014.112. View

Furudate S, Fujimura T, Kakizaki A, Kambayashi Y, Asano M, Watabe A . The possible interaction between periostin expressed by cancer stroma and tumor-associated macrophages in developing mycosis fungoides. Exp Dermatol. 2015; 25(2):107-12. DOI: 10.1111/exd.12873. View

Weber J, Gibney G, Sullivan R, Sosman J, Slingluff Jr C, Lawrence D . Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial. Lancet Oncol. 2016; 17(7):943-955. PMC: 5474305. DOI: 10.1016/S1470-2045(16)30126-7. View

Yamaguchi Y, Ono J, Masuoka M, Ohta S, Izuhara K, Ikezawa Z . Serum periostin levels are correlated with progressive skin sclerosis in patients with systemic sclerosis. Br J Dermatol. 2012; 168(4):717-25. DOI: 10.1111/bjd.12117. View

Fujimura T, Furudate S, Kakizaki A, Kambayashi Y, Haga T, Hashimoto A . Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in-transit melanoma: Two cases reports. J Dermatol. 2015; 43(6):686-9. DOI: 10.1111/1346-8138.13229. View

Fujimura T, Kambayashi Y, Furudate S, Hidaka T, Sato Y, Tanita K . Successful treatment of multiple in-transit melanomas on the leg with intensity-modulated radiotherapy and immune checkpoint inhibitors: Report of two cases. J Dermatol. 2016; 44(5):592-595. DOI: 10.1111/1346-8138.13707. View

10.

Steele C, Karim S, Leach J, Bailey P, Upstill-Goddard R, Rishi L . CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer Cell. 2016; 29(6):832-845. PMC: 4912354. DOI: 10.1016/j.ccell.2016.04.014. View

11.

Liniker E, Menzies A, Kong B, Cooper A, Ramanujam S, Lo S . Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma. Oncoimmunology. 2016; 5(9):e1214788. PMC: 5048757. DOI: 10.1080/2162402X.2016.1214788. View

12.

Fujimura T, Hidaka T, Kambayashi Y, Furudate S, Kakizaki A, Tono H . Phase I study of nivolumab combined with IFN-β for patients with advanced melanoma. Oncotarget. 2017; 8(41):71181-71187. PMC: 5642629. DOI: 10.18632/oncotarget.17090. View

13.

Long G, Stroyakovskiy D, Gogas H, Levchenko E, De Braud F, Larkin J . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014; 371(20):1877-88. DOI: 10.1056/NEJMoa1406037. View

14.

Fujimura T, Kakizaki A, Furudate S, Aiba S . A possible interaction between periostin and CD163 skin-resident macrophages in pemphigus vulgaris and bullous pemphigoid. Exp Dermatol. 2016; 26(12):1193-1198. DOI: 10.1111/exd.13157. View

15.

Noy R, Pollard J . Tumor-associated macrophages: from mechanisms to therapy. Immunity. 2014; 41(1):49-61. PMC: 4137410. DOI: 10.1016/j.immuni.2014.06.010. View

16.

Komohara Y, Fujiwara Y, Ohnishi K, Takeya M . Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy. Adv Drug Deliv Rev. 2015; 99(Pt B):180-185. DOI: 10.1016/j.addr.2015.11.009. View

17.

Gordon S, Martinez F . Alternative activation of macrophages: mechanism and functions. Immunity. 2010; 32(5):593-604. DOI: 10.1016/j.immuni.2010.05.007. View

18.

Fujimura T, Kambayashi Y, Furudate S, Asano M, Kakizaki A, Aiba S . Receptor Activator of NF-κB Ligand Promotes the Production of CCL17 from RANK+ M2 Macrophages. J Invest Dermatol. 2015; 135(11):2884-2887. DOI: 10.1038/jid.2015.209. View

19.

Fukuda K, Sugihara E, Ohta S, Izuhara K, Funakoshi T, Amagai M . Periostin Is a Key Niche Component for Wound Metastasis of Melanoma. PLoS One. 2015; 10(6):e0129704. PMC: 4471156. DOI: 10.1371/journal.pone.0129704. View

20.

Robert C, Long G, Brady B, Dutriaux C, Maio M, Mortier L . Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2014; 372(4):320-30. DOI: 10.1056/NEJMoa1412082. View